Viral escape and T-cell immunity during ganciclovir treatment of cytomegalovirus infection: case report of a pancreatico-renal transplant recipient1
- 15 March 2003
- journal article
- case report
- Published by Wolters Kluwer Health in Transplantation
- Vol. 75 (5) , 724-727
- https://doi.org/10.1097/01.tp.0000052664.18029.e6
Abstract
Pancreas-kidney transplant recipients are at high risk for cytomegalovirus (CMV) disease despite prophylactic ganciclovir therapy. Because the impact of antiviral therapy on anti-CMV immune reactions is unknown, CMV-specific T-cell subsets in primary and recurrent CMV infection were analyzed in a pancreas-kidney transplant case study. Major histocompatibility complex class I tetramers were used to detect peripheral CMV pp65-specific CD8 T cells. Intracellular cytokine staining was used to determine the frequency of CMV-specific CD4 T cells. Conventional virologic parameters and routine laboratory parameters were monitored. For ganciclovir resistance testing, CMV-UL97 genotyping was performed. Despite prophylactic ganciclovir therapy, primary CMV infection induced in vivo expansion of activated CMV-specific CD8 T cells. Interestingly, viral dissemination during recurrent CMV disease was a result of partially ganciclovir-resistant CMV. Recovery after discontinued ganciclovir treatment was associated with the expansion of CMV-specific CD4 T cells. Immunologic monitoring may contribute to clinical management of recurrent CMV disease.Keywords
This publication has 9 references indexed in Scilit:
- Activated virus-specific T cells are early indicators of anti-CMV immune reactions in liver transplant patientsGastroenterology, 2002
- RISK FACTORS AND IMPACT OF CYTOMEGALOVIRUS DISEASE IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATIONTransplantation, 2001
- Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein*Journal of Medical Virology, 2001
- Prophylaxis for CMV should not now replace pre‐emptive therapy in solid organ transplantationReviews in Medical Virology, 2001
- Patterns of cytomegalovirus infection in simultaneous kidney–pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxisTransplant Infectious Disease, 2001
- Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplantsThe Lancet, 2000
- LONG-TERM RESULTS OF PANCREAS TRANSPLANTATION UNDER TACROLIMUS IMMUNOSUPPRESSION1Transplantation, 1999
- DEVELOPMENT OF GANCICLOVIR RESISTANCE DURING TREATMENT OF PRIMARY CYTOMEGALOVIRUS INFECTION AFTER LIVER TRANSPLANTATION1Transplantation, 1997
- Treatment of Recurrent Cytomegalovirus Disease in Patients Receiving Solid Organ TransplantsArchives of Surgery, 1993